Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 01, 2026
TickeronGET DAILY SIGNALS
Supernus Pharmaceuticals (SUPN): Analyst Consensus Points to +48% Upside to $62 Target

Supernus Pharmaceuticals (SUPN): Analyst Consensus Points to +48% Upside to $62 Target

Key Takeaways

  • The central target of $62 is the arithmetic mean of six verified analyst price targets, rounded from roughly $62.17, with individual targets ranging from $55 to $67.
  • The latest verified close is about $41.92, meaning the target implies an upside of roughly 48% — a very large move from current levels.
  • Analyst views are mostly bullish but not uniform: five firms carry Buy-equivalent ratings, while Stifel holds a Neutral/Hold rating at $55.
  • Strongest supports include record quarterly revenue, raised 2026 guidance, and the pending transformational merger with Indivior Pharmaceuticals.
  • Biggest risks are integration execution, a GAAP net loss for the first nine months, and targets that may not fully reflect the post-merger combined company.
  • Readers can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
  • Explore Trending AI Robots to see AI-driven trading strategies in action.

Breaking Down the Analyst Targets

Supernus Pharmaceuticals, Inc. (SUPN) is a biopharmaceutical company focused on central nervous system (CNS) diseases, including ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine. It is a stock, not an exchange-traded fund.

Reviewing the most recent published targets from covering firms yields six distinct figures. Bank of America Securities (Chi Meng Fong) holds a Buy with a target of $55, lowered from $60 in mid-October; TD Cowen (Stacy Ku) maintains a Buy at $65; Piper Sandler reiterates a Buy at $66; Jefferies maintains a Buy at $65; Cantor Fitzgerald (Kristen Kluska) has a Buy at $67; and Stifel Nicolaus (Annabel Samimy) carries a Hold at $55. The resulting range is $55 to $67, and the arithmetic mean is about $62.17, rounded to $62. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Views differ mainly on the launch trajectory of Onapgo and on how much credit to give the pending Indivior combination. BofA's $55 and Stifel's $55 reflect a more cautious stance on near-term launch economics, while the $65-plus targets lean on the company's growth-product momentum and merger-driven scale. Notably, several targets predate the merger's final stages and may not yet reflect the combined entity's outlook.

Current Market Position and Path Toward the Target

With the stock near $41.92, reaching $62 requires an increase of roughly 48% — a very large move. The shares sit well below their 52-week high of about $59.68 but above the 52-week low near $37.54, and they have lost roughly 17% year-to-date despite a stronger broad market.

The path toward the target would likely depend on the combined company realizing its forecast cost synergies, sustaining double-digit prescription growth in products such as Qelbree and Zurzuvae, and converting improved operating leverage into higher earnings. In the third quarter of 2026, Supernus reported record total revenue of $226.8 million, up 18% year over year, and raised full-year standalone revenue guidance to a range of $875 million to $900 million, with non-GAAP operating earnings of $160 million to $180 million.

What Could Support a Move Toward the Target

  • Growth-product momentum: Combined revenue from Qelbree, Zurzuvae, Onapgo, and Gocovri rose about 43% year over year in the third quarter.
  • Onapgo exclusivity: The FDA granted seven years of orphan drug exclusivity for Onapgo in advanced Parkinson's disease, a meaningful competitive moat.
  • Zurzuvae collaboration: Supernus reported $42 million in collaboration revenue for the quarter, with U.S. sales reported by Biogen up about 53%.
  • Indivior merger: Shareholders approved the deal, with management citing roughly $125 million in expected annual cost synergies and a combined portfolio spanning psychiatry, neurology, and addiction.

What Could Prevent the Target From Being Reached

  • Integration risk: Combining with Indivior is complex, and cost-synergy targets are not guaranteed to be realized on schedule.
  • GAAP profitability: The company posted a GAAP net loss of about $39.8 million for the first nine months of 2026, though it was GAAP-profitable in the third quarter.
  • Launch execution: Onapgo enrollment forms have hovered around 400 per quarter, suggesting new patient starts could plateau without further acceleration.
  • Valuation and sentiment: A 48% gain implies the market must re-rate the stock meaningfully, which could stall if growth disappoints or if analyst targets are revised lower post-merger.

Technical Levels and Market Structure

The stock's 52-week range of roughly $37.54 to $59.68 provides a useful reference. A move toward $62 would require the shares to clear prior resistance near the $59.68 high and break into new 52-week territory, with the psychological $60 level as an intermediate marker. On the downside, the area near $40 and the 52-week low near $37.54 are durable reference levels that would need to hold for the target to remain in view.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of around 12 months, though the actual horizon varies by firm and several current targets predate the merger's closing. Investors should watch the completion of the Indivior transaction, the first combined-company 2027 guidance expected in February, Onapgo prescription trends, Zurzuvae sales growth reported by Biogen, and any post-merger analyst target revisions. Pipeline data for SPN-820 and SPN-817 are further out and less likely to move the near-term target debate.

Final Assessment

The $62 central target reflects the arithmetic mean of six analyst targets spanning $55 to $67, and it sits roughly 48% above the recent price near $41.92. Achieving it would require the combined Supernus-Indivior company to deliver on cost synergies, sustain growth-product momentum, and convince the market to assign a higher multiple. The principal obstacles are integration execution, persistent GAAP losses on a year-to-date basis, and the possibility that post-merger target revisions moderate the current range. Analysts broadly lean bullish, but the $55-to-$67 spread shows genuine disagreement about the pace of the launch and the merger's value. No outcome is guaranteed; the trajectory will hinge on combined-company guidance and near-term commercial execution.

Using AI Daily Buy/Sell Signals in My Research

In my own analysis workflow, Tickeron’s AI Daily Buy/Sell Signals provide an efficient way to monitor momentum shifts in names like SUPN. The system scans thousands of stocks in real time and flags Buy, Sell, or Hold signals based on technical patterns and market conditions, which helps me cross-check analyst views without relying solely on manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SUPN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SUPN's RSI Indicator ascends from oversold territory

The RSI Oscillator for SUPN moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 23 of the 28 cases the stock moved higher. This puts the odds of a move higher at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on SUPN as a result. In 74 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for SUPN just turned positive on November 11, 2026. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.

Following a +6.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 223 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

The Aroon Indicator for SUPN entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.477) is normal, around the industry mean (6.379). P/E Ratio (-13.625) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.202). SUPN's Dividend Yield (1.243) is considerably higher than the industry average of (0.061). P/S Ratio (2.863) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SUPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 38% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 63
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 6 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer for the treatment of central nervous system

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
9715 Key West Avenue
Phone
+1 301 838-2500
Employees
778
Web
https://www.supernus.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.